FDA Approves Fruzaqla (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Fruzaqla is the First Targeted Therapy Approved for Metastatic Colorectal Cancer (mCRC) Regardless of Biomarker Status in More Than a Decade Fruzaqla Plus Best Supportive Care Demonstrated Significant Improvements in Overall Survival, with...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news